EGM
RVNC

Engineers Gate Manager’s Revance Therapeutics, Inc. RVNC Stock Holding History

Engineers Gate Manager’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-48,096
Closed -$250K – 2656
2024
Q3 		$250K Buy
+48,096
New +$239K ﹤0.01% 1702
2024
Q1 		– Sell
-28,408
Closed -$250K – 2374
2023
Q4 		$250K Sell
28,408
-9,964
-26% -$81.6K 0.01% 1547
2023
Q3 		$440K Sell
38,372
-17,673
-32% -$340K 0.02% 1116
2023
Q2 		$1.42M Buy
56,045
+15,361
+38% +$479K 0.05% 507
2023
Q1 		$1.31M Buy
40,684
+7,167
+21% +$223K 0.05% 476
2022
Q4 		$619K Buy
+33,517
New +$767K 0.04% 768
2020
Q1 		– Sell
-12,931
Closed -$210K – 2005
2019
Q4 		$210K Buy
+12,931
New +$201K 0.01% 1448

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Engineers Gate Manager's RVNC Position: Q4 2024 in Review

Engineers Gate Manager sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 48,096 shares — an estimated $250K sold.

Engineers Gate Manager first reported a position in RVNC in Q4 2019 and held it in 7 quarters. The position peaked at $1.42M in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Engineers Gate Manager reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 48,096 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $250K.
  • Engineers Gate Manager first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 7 quarters.
  • Engineers Gate Manager's Revance Therapeutics, Inc. position peaked at $1.42M in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Engineers Gate Manager's 13F filing for Q4 2024, filed 14 Feb 2025.